Document is current
Any future updates will be listed below
-
Authors
Renz, Alina https://orcid.org/0000-0003-3851-9978
Hohner, Mirjam
Jami, Raphaël
Breitenbach, Maximilian
Josephs-Spaulding, Jonathan
Dürrwald, Johanna
Best, Lena https://orcid.org/0000-0003-2772-153X
Dulière, Victoria
Mialon, Chloé
Bader, Stefanie M.
Marinos, Georgios https://orcid.org/0000-0002-6443-7696
Leonidou, Nantia https://orcid.org/0000-0002-0248-6679
Cabreiro, Filipe https://orcid.org/0000-0002-3696-4843
Pellegrini, Marc https://orcid.org/0000-0003-3627-3126
Doerflinger, Marcel
Rosa-Calatrava, Manuel
Pizzorno, Andrés https://orcid.org/0000-0002-0918-6804
Dräger, Andreas https://orcid.org/0000-0002-1240-5553
Schindler, Michael https://orcid.org/0000-0001-8989-5813
Kaleta, Christoph https://orcid.org/0000-0001-8004-9514
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EXC2167, CRC1182)
- License Information
-
More Information
Article History
Received: 10 June 2024
Accepted: 30 April 2025
First Online: 23 May 2025
Competing interests
: The authors declare the following competing interests: A.R., M.H., L.B., J.J.S., A.D., M.S., and C.K. have submitted a patent application for using phenformin and atpenin A5 as broad-spectrum antivirals. All other authors declare no competing interests.
